Difference between revisions of "Vandetanib (Caprelsa)"
m |
m |
||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[Thyroid cancer]] | + | *[[Thyroid cancer | Medullary thyroid cancer]] |
==Patient drug information== | ==Patient drug information== | ||
*[http://www1.astrazeneca-us.com/pi/vandetanib.pdf#page=6 Vandetanib (Caprelsa) package insert PDF pages 6-8]<ref>[http://www1.astrazeneca-us.com/pi/vandetanib.pdf#page=6 Vandetanib (Caprelsa) package insert PDF pages 6-8]</ref> | *[http://www1.astrazeneca-us.com/pi/vandetanib.pdf#page=6 Vandetanib (Caprelsa) package insert PDF pages 6-8]<ref>[http://www1.astrazeneca-us.com/pi/vandetanib.pdf#page=6 Vandetanib (Caprelsa) package insert PDF pages 6-8]</ref> | ||
*[http://www.uptodate.com/contents/vandetanib-patient-drug-information Vandetanib (Caprelsa) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/vandetanib-patient-drug-information Vandetanib (Caprelsa) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/vandetanib-patient-drug-information Vandetanib (Caprelsa) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/vandetanib-patient-drug-information Vandetanib (Caprelsa) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 4/6/2011: Initial FDA approval "for the treatment of symptomatic or progressive [[Thyroid cancer | medullary thyroid cancer]] in patients with unresectable locally advanced or metastatic disease." | ||
==Also known as== | ==Also known as== | ||
| Line 19: | Line 22: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Oral chemotherapy]] | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
[[Category:EGFR inhibitors]] | [[Category:EGFR inhibitors]] | ||
[[Category:RET inhibitors]] | [[Category:RET inhibitors]] | ||
| + | [[Category:SRC inhibitors]] | ||
[[Category:VEGF inhibitors]] | [[Category:VEGF inhibitors]] | ||
[[Category:Thyroid cancer medications]] | [[Category:Thyroid cancer medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 2011]] | ||
Revision as of 03:10, 17 November 2014
General information
Class/mechanism: Tyrosine kinase inhibitor of EGFR (epidermal growth factor receptor), VEGF (vascular endothelial cell growth factor), RET (rearranged during transfection), BRK (breast tumor kinase/protein tyrosine kinase 6), TIE2, EPH, Src. Inhibits angiogenesis, endothelial cell migration, and tumor growth.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Vandetanib (Caprelsa) package insert PDF pages 6-8[5]
- Vandetanib (Caprelsa) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 4/6/2011: Initial FDA approval "for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease."
Also known as
Zactima, ZD6474.
References
- ↑ 1.0 1.1 Vandetanib (Caprelsa) package insert
- ↑ Vandetanib (Caprelsa) package insert (locally hosted backup)
- ↑ Caprelsa manufacturer's website
- ↑ Caprelsa Risk Evaluation and Mitigation Strategy (REMS) Program
- ↑ Vandetanib (Caprelsa) package insert PDF pages 6-8
- ↑ Vandetanib (Caprelsa) patient drug information (UpToDate)